Search ELIXIR-funded activities

ELIXIR's funded activities guide future service development, drive standards adoption and connect ELIXIR Nodes (see Who we are).

Name of study Duration
Interoperability of protein resources for drug discovery: Improving Links Between the Human Protein Atlas (HPA) and EMBL-EBI Protein Resources
Interoperability Services for the Cloud
Interoperability with a Purpose
Interoperable controlled-access big data transfer for ELIXIR - expanding EGA collaboration
Interpretation of phenotypic and genotypic variation for rare diseases in terms of biological pathways
LEAP - Linking Expertise and Analysis in Pathways
Life-cycle long data management and handling of sensitive data
Literature-Data Integration
Local/Federated EGA
Long Term Sustainability
Making container services integratable, sustainable and widely adopted
Mapping the landscape of Biocuration in ELIXIR: Practice, capability and training requirements
Marine metagenomics: towards user centric services
Metabolite Identification
Metrics discovery and implementation in life sciences
Microbial Biotechnology Community
Mining the proteome: Enabling automated processing and analysis of large-scale proteomics data
Odyssey: Connecting molecular and geographical biodiversity data
Open access tools for effective management of ELIXIR Nodes based on collaborative work developed in ELIXIR-CONVERGE, RITRAIN, RItrainPlus and EMMRI
Packaging, containerisation & deployment (2022-23)
Packaging, containerisation and deployment
Performance benchmarking & technical monitoring (2022-23)
Performance benchmarking and technical monitoring
Private, virtual workspaces in the data infrastructure: ELIXIR-Facing Cloud Support and Virtual Machines
Proteopedia - A case study for long-term sustainability of an ELIXIR service
Rare Disease test case for ELIXIR Interoperability backbone
Rare Diseases Infrastructure
Reference hCNV datasets, use-case workflows and benchmarking
Registry of bioinformatics tool information and identifiers
Safeguarding resources that link genes with disease: Establishing the EGA as a Joint Venture